Decitabine Compared with Low-Dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed Acute Myeloid Leukemia: A Pilot Study of Safety, Efficacy, and Cost-Effectiveness

Table 2

Comparison of outcomes in the study groups.

Outcome	Decitabine ()	Low-dose cytarabine ()
Number of cycles received
Median	4	4
Range	(1–7)	(1–14)
Overall survival (in months)
Median	5.5	5.5
Range	(0.5–13)	(0.5–17.10)
Mean survival time	5.38	6.27
Testing equality of survival distribution
Log-rank test, value	0.5586
Hazard ratio (95% Wald confidence interval)	0.811 (0.390–1.687)
Toxicity, (%)
Febrile neutropenia	5 (33.33)	5 (33.33)
Anemia	8 (53.33)	7 (46.67)
Neutropenia	7 (46.67)	8 (53.33)
Thrombocytopenia	8 (53.33)	8 (53.33)
Mucositis	4 (26.67)	4 (26.67)
Hypocalcemia	3 (20.00)	2 (13.33)
Hypokalemia	2 (13.33)	2 (13.33)
Fatigue	4 (26.67)	5 (33.33)